Affordable Access

Phase II study of liarozole in advanced non-small cell lung cancer

Authors
  • O'Byrne, Kenneth J.
  • Han, C.
  • Mitchell, K.
  • Lane, D.
  • Carmichael, J.
  • Harris, A. L.
  • Talbot, D. C.
Publication Date
Jan 01, 1998
Source
Queensland University of Technology ePrints Archive
Keywords
License
Unknown
External links

Abstract

The aim of this phase II study was to investigate the efficacy and tolerability of liarozole, a novel benzimidazole derivative, in non-small cell lung cancer (NSCLC). Liarozole 300 mg twice daily orally was evaluated in 14 patients with stage IIIB and IV NSCLC. 8 patients had received prior treatment with chemotherapy and/or radiotheraphy. WHO toxocity grading and response criteria were used. Liarozole was well tolerated. Grade 2 toxicities included alopecia (1 patient), dermatological toxicity (5 patients), dry mouth (2 patients) and nausea and vomiting (2 patients). Leukocytosis was seen in 5 patients, including 2 cases with an elevated white cell count pretreatment. Liarozole was discontinued in 1 patient who developed intolerable progressive pruritis associated with an erythematous rash. No objective tumour response was seen, all 14 patients developing progressive disease with 4 months of commencing treatment. Liarozole was well tolerated but was ineffective as single as single agent therapy in the management of NSCLC. The side-effect profile was compatible with inhibition of retinoic acid degradation.

Report this publication

Statistics

Seen <100 times